(2026) -
Chronological (1700 items)
(All links open in new tab)
| Oct 15, 2026 |
Marijuana Is A Popular Tool For People Trying To Quit Smoking Cigarettes, Rivaling Prescription Nicotine Cessation Medications, Study Shows
Almost as many people are using marijuana to help them quit smoking cigarettes as are using prescription nicotine cessation aids, according to a new study conducted by officials with the U.S. Department of Veterans Affairs (VA) and other institutions. The research, however, raises questions about potential side effects experienced by people who are using cannabis to quit tobacco products. |
|---|---|
| Oct 15, 2026 |
Nearly one-third of cannabis consumers say they have completely cut out alcohol
Nearly one-third of cannabis consumers say they have completely replaced alcohol with cannabis, while almost two-thirds report drinking less as a result of their cannabis use, according to a new survey conducted in the United States. The poll was conducted as part of Sober October, an annual initiative encouraging people to abstain from alcohol for a month, by medical cannabis telehealth company NuggMD. Over 1000 cannabis consumers were polled between 24 and 26 September 2026. |
| Oct 15, 2026 |
Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company
TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabis company, today announced that it has completed its previously announced acquisition of CanAdelaar B.V. ("CanAdelaar"), the largest cannabis company operating within the Netherlands' adult-use cannabis pilot program, the Wietexperiment. |
| Oct 15, 2026 |
Irradiated Medical Cannabis and the Science Behind the Debate
Much of the discussion involving irradiated medical cannabis centres on whether the treatment affects THC or terpenes. Those are reasonable questions, but I think the microbiology deserves an equal share of the attention. Irradiation can substantially reduce the number of viable microorganisms in flower, but any mould that has already grown remains physically present after treatment. |
| Oct 15, 2026 |
Cannabis doesn’t make you violent – despite what recent reports have claimed
n what looked like a return to the dark days of Reefer Madness – a 1936 film that portrayed cannabis as a drug that could drive people to madness and murder – a recent article in the Daily Telegraph claimed that cannabis users are “twice as likely to be violent”. The claim comes from a systematic review by King’s College London that combined 63 studies covering more than 265,000 people. The researchers did, indeed, find a link between cannabis use and violence, but the headline overstates what the numbers can tell us. There are three reasons to be cautious: other factors that could explain the link (known as confounders), the way the studies were designed, and potential biases in how the data was gathered. |
| Oct 14, 2026 |
Tilray Medical Facility in Portugal Gains Approval for In-House Testing
Portugal’s National Authority of Medicines and Health Products has approved the quality control laboratory at Tilray Medical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The company says the INFARMED approval gives Tilray Medical greater control over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for medical cannabis supply across regulated international markets. |
| Oct 14, 2026 |
New cannabis packaging business launches in Canada
CropPak has launched a new cannabis packaging company and website created specifically for cannabis growers and brands. The launch marks the start of operations for the Abbotsford-based business, which was established around a factory-direct packaging model intended to help cultivators manage packaging expenses as tighter operating margins increase the importance of cost control. |
| Oct 14, 2026 |
Herbal Dispatch Ships 3,000 Units of 2026 Happy Hour Holiday Cannabis Calendar to BCLDB Following Sold-Out 2025 Edition
Herbal Dispatch (LUFFF) sold and shipped 3,000 units of its 2026 Happy Hour Holiday Cannabis Calendar to the British Columbia Liquor Distribution Branch. The shipment represents over $100,000 in wholesale sales at $34.99 per unit, with an approximate gross margin of 42%. Produced with Coast Mountain Cannabis, the Calendar will reach BC Cannabis Stores and private licensed retailers. Production increased to 4,200 units, about 25% above the sold-out 2025 run of 3,350 units. |
| Oct 14, 2026 |
Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside
EDMONTON, AB, Oct. 14, 2026 /CNW/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the Canadian-based leading global medical cannabis company, today reconfirms that the Board of Directors (the "Board"), on the unanimous recommendation of a special committee of independent directors (the "Special Committee"), unanimously recommends that shareholders REJECT the hostile offer by Curaleaf Holdings, Inc. ("Curaleaf") (TSX: CURA) (OTCQX: CURLF) for all of the issued and outstanding common shares of the Company, as revised in the Notice of Variation, Change and Extension filed by Curaleaf on October 6, 2026 (the "Hostile Bid"). "Curaleaf's revised offer still does not reflect the value of the company Aurora shareholders own today. Aurora is debt-free with a strong cash position, and we believe the revised Hostile Bid continues to ask shareholders to give up that strength, and their future upside, at a discount," said Miguel Martin, Executive Chairman and CEO of Aurora. |
| Oct 14, 2026 |
German Organizations Criticize Changes To Cannabis Flower Reimbursements
This month, the Health Committee of the German Bundestag held a hearing to discuss the coalition’s proposed amendments to the Statutory Health Insurance (SHI) Contribution Rate Stabilization Act. The measure was approved before the Bundestag’s summer recess. The German Hemp Association (DHV) issued a statement leading up to the recent Health Committee hearing. |
| Oct 14, 2026 |
The Aurora MĂ©nage Ă Trois: Three Shifts in Seven Days
Curaleaf Holdings’ battle to acquire Aurora Cannabis has shifted in favour of the Canadian producer on multiple fronts over the last week. Not only has Curaleaf raised its hostile bid by 25% to an implied US$5.00 per share, but media reports suggest the BAT-backed (British American Tobacco) Organigram Global is now also in contention to merge with Aurora. Alongside the completion of a major expansion of its German EU-GMP facility expected to double its annual flower production, Aurora is now in a considerably stronger position than just a week earlier. |
| Oct 14, 2026 |
Cannabis prices down $1 to date in 2026
Cannabis prices hit a new low in September, falling to an average $6.57 per gram. Total sales in both the adult-use and medical markets also fell between August and September. The average price per gram of marijuana has fallen by just over a dollar in 2026. In January, marijuana averaged $7.63 a gram. Prices have generally fallen each month, except between April and May where the price per gram increased by nine cents. Marijuana prices peaked in March 2024, at an average $12.51 per gram and have largely fallen month-over-month since. The average price per adult-use product has also followed the same trend. In September, the average adult-use product cost $27.24, down from $28.09 the previous month. |
| Oct 14, 2026 |
Why Aurora Cannabis (TSX:ACB) Is Defending Its Medical Cannabis Strategy Against Curaleaf's Revised Bid
Aurora Cannabis Inc. (TSX:ACB) is in the spotlight because it is defending against a hostile take-over bid from Curaleaf Holdings, Inc., which was revised in early October to an offer that Curaleaf values at US$5.00 per Aurora share. Aurora's board had said it would give a formal recommendation on the revised terms after its special committee reviews them. In the meantime it has told shareholders to take no action. The company's case for independence rests on a debt-free balance sheet, a growing international medical cannabis business and EU-GMP certified production capacity. |
| Oct 13, 2026 |
Puerto Rico Rolls Back Workplace Protections for Medical Cannabis Patients. Who’s Left Out?
Puerto Rico’s new Act 204-2026 creates an exception to workplace protections for registered medical cannabis patients in certain safety-sensitive transportation roles. The law does not eliminate the medical cannabis program or protections for patients generally, but it gives employers a new legal basis for employment decisions involving covered workers. |
| Oct 13, 2026 |
Clinical Trials Begin in U.S. for First Cannabis-Based Medicine for Chronic Pain
The first clinical trials in the United States for a cannabis-based medicine for chronic pain are getting underway. New York State has authorized a clinical trial of VER-01 in patients with chronic low back pain from lumbosacral radiculopathy, commonly known as sciatica. VER-01 was developed by Vertanical, a German biopharmaceutical company, and recently became available by prescription in Europe, where it is sold under the brand name Exilby. Exilby is a full spectrum extract derived from THC, CBD and terpenes found in cannabis sativa. Unlike other cannabis-based medicines already on the market, such as Epidolex and Marinol, which are used to treat epilepsy and improve appetite, Exilby was specifically developed to treat chronic pain. |
| Oct 13, 2026 |
Canadian cannabis company Organigram enters fight for Aurora
The fight to acquire Aurora Cannabis may include a global tobacco giant. In a signal that Curaleaf Holdings’ hostile takeover bid could be undercut, Organigram Holdings, a Canadian licensed producer partly owned by British American Tobacco, is also interested in acquiring Aurora, cannabis newsletter Cultivated reported. |
| Oct 13, 2026 |
How Many U.S. Adults Consume Cannabis?
A team of researchers affiliated with the U.S. National Institutes of Health recently conducted a study examining, among other things, the rate of cannabis use by adults in the United States. The study’s findings were published in the journal Addictive Behaviors. The study used data from the 2024 Health Information National Trends Survey, which asked about past 12-month cannabis use. The survey also asked about which consumption method cannabis consumers used, such as smoking, vaping, dabbing, edibles, drinkables, and topicals. The study also asked about tobacco use. “An estimated 23.1% of US adults reported past 12-month cannabis use: 62.6% smoked, 57.6% consumed, 40.1% vaped, 15.2% applied lotion, and 12.4% dabbed, with over half (52.7%) endorsing >1 route of administration.” the study found. |
| Oct 13, 2026 |
U.S. Legal Marijuana Sales Reach $2.52 Billion in September, Bringing 2026 Total to $21.6 Billion
Legal marijuana sales across the United States reached approximately $2.52 billion in September, bringing the estimated total for the first nine months of 2026 to $21.6 billion, according to an analysis by The Marijuana Herald. The September estimate was approximately 1.1% below the $2.55 billion reported for August, although daily sales were slightly higher at $84 million compared to $82 million. September’s sales were also around 8% higher than the $2.34 billion sold in September, 2025. The roughly $2.52 billion in sales brings 2026’s year-to-date total to $21.6 billion. |
| Oct 13, 2026 |
Cannabis Stocks in 2026: What Is Listed, What Is Next and How the Market Trades
On April 22, 2026, US Acting Attorney General Todd Blanche signed an order moving cannabis under a state medical licence and any FDA-approved cannabis drugs to Schedule III, formally recognising its medical value and unlocking DEA registration for commercial operators for the first time. While medical cannabis remained in Schedule I of the Controlled Substances Act (CSA), a company whose primary business is growing and selling cannabis could not accurately state that it complied with federal law and thus couldn’t meet the listing requirements for both NYSE and NASDAQ. As such, until this change, cannabis operators have been effectively locked out of major US exchanges due to the federal illegality of cannabis. For the first time in the industry’s history, US cannabis operators had a path to list their stocks on blue-chip exchanges. |
| Oct 13, 2026 |
Colorado’s Weed Regulator Can Afford 84 of Its 158 Staffers: Four States on What Legalization Left Unfinished.
Colorado’s cannabis regulator is authorized for roughly 158 staff positions. It has about 84 employees. The Marijuana Enforcement Division relies heavily on the application and licensing fees it collects from the industry it oversees, and as the state’s market has slowed, so has the money. Raising fees to close the gap, says Dominique D. Mendiola, the division’s senior director, “risks adding pressure to businesses already navigating a declining market.” It is the kind of problem nobody campaigned on. Legalization was sold as a finish line. More than a decade after the first adult-use sales, the governments running these markets describe it as the start of a job that keeps changing: fixing early decisions, catching up on equity, funding regulators and now bracing for whatever Washington does next. |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85